SOC TELEMED INC (TLMD)

Common Stock

3  0 (0%)

After market: 3 0 (0%)

Fundamental Rating

1

Overall TLMD gets a fundamental rating of 1 out of 10. We evaluated TLMD against 118 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of TLMD have multiple concerns. TLMD does not seem to be growing, but still is valued expensively.



0

1. Profitability

1.1 Basic Checks

TLMD had negative earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA -31.66%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -57.36%
PM (TTM) -69.61%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

3

2. Health

2.1 Basic Checks

TLMD has more shares outstanding than it did 1 year ago.
There is no outstanding debt for TLMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

TLMD has an Altman-Z score of 0.35. This is a bad value and indicates that TLMD is not financially healthy and even has some risk of bankruptcy.
TLMD has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF N/A
Altman-Z 0.35
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

TLMD has a Current Ratio of 3.33. This indicates that TLMD is financially healthy and has no problem in meeting its short term obligations.
TLMD has a Quick Ratio of 3.25. This indicates that TLMD is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 3.33
Quick Ratio 3.25

2

3. Growth

3.1 Past

The earnings per share for TLMD have decreased strongly by -192688.57% in the last year.
EPS 1Y (TTM)-192688.57%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-75.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to decrease by -6.44% on average over the next years.
The Revenue is expected to grow by 28.52% on average over the next years. This is a very strong growth
EPS Next Y-42.09%
EPS Next 2Y-11.37%
EPS Next 3Y-5.16%
EPS Next 5Y-6.44%
Revenue Next Year61.44%
Revenue Next 2Y43.62%
Revenue Next 3Y33.9%
Revenue Next 5Y28.53%

3.3 Evolution

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TLMD. In the last year negative earnings were reported.
Also next year TLMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as TLMD's earnings are expected to decrease with -5.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.37%
EPS Next 3Y-5.16%

0

5. Dividend

5.1 Amount

TLMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

SOC TELEMED INC

NASDAQ:TLMD (4/5/2022, 7:00:02 PM)

After market: 3 0 (0%)

3

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap303.99M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.66%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -57.36%
PM (TTM) -69.61%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.41
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.33
Quick Ratio 3.25
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-192688.57%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-42.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y